NantKwest, Inc. (NK): Price and Financial Metrics


NantKwest, Inc. (NK)

Today's Latest Price: $7.87 USD

0.45 (-5.41%)

Updated Nov 23 4:00pm

Add NK to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

NK Stock Summary

  • NK's price/sales ratio is 9,126.16; that's higher than the P/S ratio of 99.77% of US stocks.
  • Revenue growth over the past 12 months for NantKwest Inc comes in at 141.46%, a number that bests 95.95% of the US stocks we're tracking.
  • In terms of volatility of its share price, NK is more volatile than 91.69% of stocks we're observing.
  • Stocks that are quantitatively similar to NK, based on their financial statements, market capitalization, and price volatility, are PSTI, VTVT, AUPH, PRKR, and MRSN.
  • Visit NK's SEC page to see the company's official filings. To visit the company's web site, go to www.nantkwest.com.

NK Stock Price Chart Interactive Chart >

Price chart for NK

NK Price/Volume Stats

Current price $7.87 52-week high $15.70
Prev. close $8.32 52-week low $1.14
Day low $7.81 Volume 739,433
Day high $8.42 Avg. volume 1,727,072
50-day MA $8.05 Dividend yield N/A
200-day MA $7.30 Market Cap 854.63M

NantKwest, Inc. (NK) Company Bio


NantKwest is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. The company was founded in 2002 and is based in Cardiff-by-the-Sea, California.


NK Latest News Stream


Event/Time News Detail
Loading, please wait...

NK Latest Social Stream


Loading social stream, please wait...

View Full NK Social Stream

Latest NK News From Around the Web

Below are the latest news stories about NantKwest Inc that investors may wish to consider to help them evaluate NK as an investment opportunity.

NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET. The conference presentation will be available on the NantKwest website, NantKwest.com. An archived replay will be available on the website for approximately 30 days. About NantKwest NantKwest (NASDA

Business Wire | September 21, 2020

NantKwest's NK-92 bioanalytical testing line licensed to Fresenius Kabi SwissBioSim

NantKwest's ([[NK]] +2.0%) affiliate and exclusively-licensed distributor of its proprietary off-the-shelf NK-92® natural killer cells, Brink Biologics, has licensed its natural killer-based bioanalytical testing solution, to Fresenius Kabi SwissBioSim.Brink Biologics offers NK-92 based cell lines as part of its Neukopanel portfolio for laboratory based bioanalytical testing....

Seeking Alpha | September 10, 2020

NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics

EL SEGUNDO, Calif. & CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately held immunotherapy company, today announced the signing of a definitive agreement to jointly develop, manufacture, market, and commercialize therapeutics and vaccines for combating the COVID-19 pandemic. Under the terms of the definitive agreement, the two companies agree to share equally the costs incurred after

Business Wire | August 24, 2020

NantKwest in Pact with Generate Life’s CBR on potential COVID-19 treatment

Cord Blood Registry ((CBR)) by Generate Life Sciences and NantKwest ([[NK]] +6.7%) announces collaboration for development of COVID-19 treatment leveraging newborn stem cells.CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cellsPatient trials expected to begin in the fall, and both companies anticipate an FDA-approved treatment to be in the market for...

Seeking Alpha | August 10, 2020

Cord Blood Registry (CBR®) By Generate Life Sciences Partners With NantKwest To Develop COVID-19 Treatment

LOS ANGELES, and EL SEGUNDO, Calif., Aug. 10, 2020 /PRNewswire/ -- CBR® by Generate Life Sciences, the world's largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy company, today announced a collaboration to develop…

PR Newswire | August 10, 2020

Read More 'NK' Stories Here

NK Price Returns

1-mo -8.28%
3-mo 0.38%
6-mo 3.83%
1-year 539.84%
3-year 58.03%
5-year -52.65%
YTD 107.65%
2019 226.72%
2018 -74.16%
2017 -21.50%
2016 -66.99%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8184 seconds.